Sorrento Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Sorrento Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Sorrento Therapeutics Inc Strategy Report
- Understand Sorrento Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sorrento Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Sorrento Therapeutics Insights data
Headline | Published | Journalists |
---|---|---|
Deserunt mollit sunt Lorem laborum do id aliqua dolore | 21 Mar 2022 | Lorem |
LoA Update: Sorrento’s fibromyalgia candidate has improved advancement chances after Phase I trial completes | 03 Feb 2022 | William Newton |
Sorrento Therapeutics enrolls 60 of 80-patient Phase II target with abivertinib in COVID-19, with futility analysis of patient subset in potentially a month, CEO says | 10 Feb 2021 | Manasi Vaidya |
Sorrento to file a COVID-19 IND application for mAb STI-1499 in late July or early August; 24-patient Phase I study to follow soon after, execs say | 15 Jul 2020 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer